サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1753383

バイオプロダクションの世界市場

Bioproduction

出版日
ページ情報
英文 380 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
バイオプロダクションの世界市場
出版日: 2025年06月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 380 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バイオプロダクションの世界市場は2030年までに616億米ドルに達する見込み

2024年に281億米ドルと推定されるバイオプロダクションの世界市場は、2024～2030年の分析期間においてCAGR 14.0%で成長し、2030年には616億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである生物製剤＆バイオシミラー医薬品は、CAGR 16.1％を記録し、分析期間終了時には326億米ドルに達すると予測されます。ワクチン分野の成長率は、分析期間中CAGR 10.3%と推定されます。

米国市場は77億米ドルと推定、中国はCAGR19.0％で成長予測

米国のバイオプロダクション市場は、2024年に77億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに134億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは19.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ10.0%と12.6%と予測されています。欧州では、ドイツがCAGR 11.1%で成長すると予測されています。

世界のバイオプロダクション市場- 主要動向と促進要因のまとめ

バイオプロダクションが産業および治療製造の将来において戦略的重要性を増している理由とは？

バイオプロダクションは、伝統的な合成生産方法に代わる生物学的駆動力を提供し、現代の工業およびバイオ医薬品製造の重要な実現要素として急速に台頭しています。これは、治療用タンパク質、酵素、バイオ燃料、ワクチン、モノクローナル抗体、特殊化学品などの幅広い製品を生産するために、バクテリア、酵母、藻類、哺乳類細胞などの生物を使用することを指します。生物製剤、持続可能な素材、環境に優しい製造方法に対する世界の需要が高まる中、バイオプロダクションは21世紀経済のニーズに合致した、拡張性の高い持続可能なソリューションとして位置づけられています。製薬分野では、インスリン、エリスロポエチン、各種細胞・遺伝子治療薬など、化学合成では不可能な複雑な生物製剤の開発にバイオプロダクションは欠かせません。製薬業界以外でも、バイオプロダクションは化粧品、食品、農業業界において、生分解性プラスチック、植物由来の代替食肉、バイオベース原料の製造に重要な役割を果たしています。再生可能な原料を使用して高純度、高力価の物質を生産する能力により、石油ベースの製造に代わる魅力的な選択肢となっています。さらに、バイオプロダクションは循環型経済モデルをサポートし、廃棄物を削減し、温室効果ガス排出量を削減するため、世界の脱炭素戦略における優先事項となっています。生物学、工学、データサイエンスの融合により、バイオプロダクションはもはや単なる研究ニッチではなく、Global Industry Analystsが業界全体で資源を創造、消費、保全する方法を形作る、動き出した産業革命なのです。

新しいテクノロジーやツールは、バイオプロダクションのスコープと効率をどのように進化させているのでしょうか？

技術革新は、バイオプロダクションシステムの効率性、拡張性、カスタマイズ性の次の波を推進しています。合成生物学と代謝工学における画期的な進歩により、科学者は微生物を正確にプログラムし、生合成経路を最適化することで、収量を最大化し、製品別の生成を最小限に抑えることができるようになりました。CRISPR-Casやその他のゲノム編集ツールは、高度に的を絞った遺伝子改変を可能にし、菌株開発を加速させ、製品の一貫性を高めています。連続バイオプロセスやモジュール式バイオプロダクションプラットフォームは、従来のバッチプロセスに取って代わり、ダウンタイムの削減、スループットの向上、スケーラビリティの向上を実現しています。シングルユースシステム、灌流リアクター、マイクロ流体プラットフォームなどの先進的なバイオリアクター設計は、柔軟性を向上させ、生産中のリアルタイム調整を可能にしています。一方、AIと機械学習アルゴリズムは、細胞の挙動を予測し、発酵パラメーターを最適化し、上流と下流のオペレーション全体で異常を検出するために採用されています。IoTデバイスやプロセス分析技術（PAT）との統合により、モニタリング機能がさらに強化され、リアルタイムのデータ取得や動的なプロセス制御が可能となっています。さらに、高分解能クロマトグラフィー、膜ろ過、沈殿技術など、下流工程の進歩により、特に高価値の治療用途において、製品の回収率と純度が向上しています。無細胞のバイオプロダクションシステムも、生体システムの限界を回避する能力で注目を集めており、より迅速なプロトタイピングとオンデマンド合成を可能にしています。デジタル化、自動化、生物科学が融合し続ける中、バイオプロダクション業界は、規制遵守とプロセスの堅牢性を確保しながら、多様な製品需要に対応できるスマートで適応力のあるデータ主導のエコシステムへと進化しています。

世界のバイオプロダクションエコシステムの拡大を牽引している産業と地域は？

バイオプロダクションは、戦略的、規制的、または持続可能性の目標を達成するために生物学的製法を活用している、幅広い業界や地域で採用が加速しています。特にモノクローナル抗体、組換えタンパク質、ワクチン、細胞ベースの治療薬の製造において、製薬およびバイオテクノロジー部門がバイオプロダクションシステムの最大の需要者であることに変わりはありません。飲食品業界では、代替タンパク質、発酵機能性成分、サプリメントや栄養補助食品に使用される生物活性化合物の製造にバイオプロダクション技術を採用する企業が増えています。エネルギー分野では、バイオマスをエタノール、バイオディーゼル、水素などの再生可能燃料に変換するために、企業が人工微生物を使用しています。化粧品やパーソナルケアの分野でも、環境に優しい香料、着色料、乳化剤の開発にバイオプロダクションが採用されています。地域別では、北米が市場をリードしており、その原動力となっているのは、強固な研究開発インフラ、バイオテクノロジー企業の集積、イノベーションを支援する有利な規制の枠組みです。ドイツ、スイス、オランダなどがバイオエコノミー戦略、持続可能な化学、グリーン製造に注力しています。アジア太平洋は急成長している地域であり、中国、インド、日本、韓国などの国々では、急速な工業化、ライフサイエンスへの投資の増加、政府の支援イニシアティブが見られます。ラテンアメリカとアフリカは、まだ新興ではあるが、地域の生物多様性と農業廃棄物の流れを活用することで、バイオプロダクションの可能性を利用し始めています。これらすべての地域において、官民パートナーシップ、国際的な研究協力、持続可能な製品に対する消費者の需要の高まりが、バイオプロダクション市場に拍車をかけています。バイオプロダクションは、治療、産業、環境アプリケーションのいずれにおいても、従来の業界の枠や国境を越えた世界なムーブメントになりつつあります。

世界のバイオプロダクション市場の成長を促進しているものは？

世界のバイオプロダクション市場の成長は、科学的イノベーション、商業的需要、規制の勢い、そして世界の持続可能性の目標がダイナミックに組み合わさって牽引しています。最も重要な成長要因の一つは、特に慢性疾患、遺伝性疾患、希少疾患の治療における生物製剤や先端治療薬に対する需要の高まりです。これらの治療法には、バイオプロダクションプラットフォームだけが提供できる高度に専門化された生産システムが必要とされることが多いです。同時に、消費者の嗜好は、パーソナルケアから農業に至るまで、持続可能で倫理的に生産されたバイオベースの製品へとシフトしており、企業はESG基準に沿ったバイオプロダクションテクノロジーへの投資を促しています。政府や規制機関も、資金援助や税制優遇措置、バイオベースのイノベーションの承認プロセスの合理化などを通じてバイオプロダクションを支援し、極めて重要な役割を果たしています。各国が気候変動対策目標や循環型経済モデルを追求する中、バイオプロダクションは、石油化学製品への依存を減らし、廃棄物を最小限に抑え、より環境に優しい方法でエネルギーや材料を生産する能力で際立っています。さらに、最新のバイオプロダクションシステムのスケーラビリティと柔軟性は、大規模な産業アプリケーションにも、局所的なオンデマンド生産にも適しています。CDMOやバイオファウンドリーの開発は、ハイエンドのバイオプロダクション機能をアウトソーシングでコスト効率よく提供することにより、市場開拓をさらに加速させています。これらの要因が相まって、バイオプロダクションは急拡大に拍車をかけているだけでなく、バイオベースの世界経済における基盤技術となり、商品や医薬品の生産、消費、持続の未来を一新する舞台を整えつつあります。

セグメント

製品（生物製剤・バイオシミラー、ワクチン、細胞・遺伝子治療薬、核酸治療薬）;用途（関節リウマチ用途、血液疾患用途、がん用途、糖尿病用途、心血管疾患用途）;最終用途（バイオ医薬品企業最終用途、製造受託機関最終用途）

調査対象企業の例（注目の41社）

  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • BioVectra
  • Boehringer Ingelheim BioXcellence
  • Catalent, Inc.
  • Charles River Laboratories
  • Cytiva
  • Emergent BioSolutions
  • FUJIFILM Diosynth Biotechnologies
  • Genscript Biotech
  • KBI Biopharma
  • Lonza Group
  • MilliporeSigma（Merck KGaA）
  • Novartis
  • Pfizer CentreOne
  • Resilience（National Resilience, Inc.）
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Sartorius AG
  • WuXi Biologics

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36388

Global Bioproduction Market to Reach US$61.6 Billion by 2030

The global market for Bioproduction estimated at US$28.1 Billion in the year 2024, is expected to reach US$61.6 Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Biologics & Biosimilars, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$32.6 Billion by the end of the analysis period. Growth in the Vaccines segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.7 Billion While China is Forecast to Grow at 19.0% CAGR

The Bioproduction market in the U.S. is estimated at US$7.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.4 Billion by the year 2030 trailing a CAGR of 19.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 12.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Global Bioproduction Market - Key Trends & Drivers Summarized

Why Is Bioproduction Gaining Strategic Importance in the Future of Industrial and Therapeutic Manufacturing?

Bioproduction is rapidly emerging as a critical enabler of modern industrial and biopharmaceutical manufacturing, offering a biologically-driven alternative to traditional synthetic production methods. It refers to the use of living organisms-such as bacteria, yeast, algae, or mammalian cells-to produce a wide range of products, including therapeutic proteins, enzymes, biofuels, vaccines, monoclonal antibodies, and specialty chemicals. As the global demand for biologics, sustainable materials, and eco-friendly manufacturing practices rises, bioproduction is positioned as a highly scalable and sustainable solution that aligns with the needs of the 21st-century economy. In the pharmaceutical sector, bioproduction is indispensable for developing complex biologics that cannot be synthesized chemically, such as insulin, erythropoietin, and various cell and gene therapies. Outside pharma, bioproduction plays a key role in producing biodegradable plastics, plant-based meat alternatives, and bio-based ingredients in the cosmetics, food, and agriculture industries. Its ability to produce high-purity, high-potency substances using renewable feedstocks makes it an attractive alternative to petroleum-based manufacturing. Moreover, bioproduction supports circular economy models, reduces waste, and lowers greenhouse gas emissions, making it a priority in global decarbonization strategies. With its convergence of biology, engineering, and data science, bioproduction is no longer just a research niche-it’s an industrial revolution in motion, shaping how we create, consume, and conserve resources across industries.

How Are Emerging Technologies and Tools Advancing the Scope and Efficiency of Bioproduction?

Technological innovation is driving the next wave of efficiency, scalability, and customization in bioproduction systems. Key breakthroughs in synthetic biology and metabolic engineering are allowing scientists to program microorganisms with precision, optimizing biosynthetic pathways to maximize yield and minimize by-product formation. CRISPR-Cas and other genome-editing tools are enabling highly targeted genetic modifications, accelerating strain development and enhancing product consistency. Continuous bioprocessing and modular bioproduction platforms are replacing traditional batch processes, offering reduced downtime, higher throughput, and better scalability. Advanced bioreactor designs-including single-use systems, perfusion reactors, and microfluidic platforms-are improving flexibility and enabling real-time adjustments during production. Meanwhile, AI and machine learning algorithms are being employed to predict cell behavior, optimize fermentation parameters, and detect anomalies across upstream and downstream operations. Integration with IoT devices and process analytical technology (PAT) is further enhancing monitoring capabilities, allowing real-time data acquisition and dynamic process control. Furthermore, advancements in downstream processing-such as high-resolution chromatography, membrane filtration, and precipitation technologies-are improving product recovery and purity, especially in high-value therapeutic applications. Cell-free bioproduction systems are also gaining attention for their ability to bypass the limitations of living systems, enabling faster prototyping and on-demand synthesis. As digitalization, automation, and biological sciences continue to converge, the bioproduction industry is evolving into a smart, adaptive, and data-driven ecosystem capable of meeting diverse product demands while ensuring regulatory compliance and process robustness.

Which Industries and Geographies Are Driving the Expansion of the Global Bioproduction Ecosystem?

Bioproduction is experiencing accelerated adoption across a broad spectrum of industries and regions, each leveraging biological manufacturing to achieve strategic, regulatory, or sustainability goals. The pharmaceutical and biotechnology sectors remain the largest consumers of bioproduction systems, especially for the production of monoclonal antibodies, recombinant proteins, vaccines, and cell-based therapies. The food and beverage industry is increasingly adopting bioproduction techniques to create alternative proteins, fermented functional ingredients, and bioactive compounds used in supplements and nutraceuticals. In the energy sector, companies are using engineered microbes to convert biomass into renewable fuels like ethanol, biodiesel, and hydrogen. The cosmetics and personal care sectors are also embracing bioproduction to develop eco-friendly fragrances, colorants, and emulsifiers. Regionally, North America leads the market, driven by robust R&D infrastructure, a high concentration of biotech firms, and favorable regulatory frameworks that support innovation. Europe follows closely, with countries like Germany, Switzerland, and the Netherlands focusing on bioeconomy strategies, sustainable chemistry, and green manufacturing. Asia-Pacific is the fastest-growing region, with rapid industrialization, growing investment in life sciences, and supportive government initiatives in countries such as China, India, Japan, and South Korea. Latin America and Africa, while still emerging, are beginning to tap into bioproduction potential by leveraging local biodiversity and agricultural waste streams. In all these regions, public-private partnerships, international research collaborations, and rising consumer demand for sustainable products are fueling the bioproduction market. Whether in therapeutic, industrial, or environmental applications, bioproduction is becoming a global movement that cuts across traditional industry lines and national boundaries.

What Is Fueling the Growth in the Global Bioproduction Market?

The growth in the global bioproduction market is driven by a dynamic combination of scientific innovation, commercial demand, regulatory momentum, and global sustainability goals. One of the most significant growth drivers is the escalating demand for biologics and advanced therapies, particularly in the treatment of chronic, genetic, and rare diseases. These therapies often require highly specialized production systems that only bioproduction platforms can offer. Simultaneously, consumer preferences are shifting toward sustainable, ethically produced, and bio-based products in sectors ranging from personal care to agriculture-prompting companies to invest in bioproduction technologies that align with ESG criteria. Governments and regulatory agencies are also playing a pivotal role by supporting bioproduction through funding, tax incentives, and streamlined approval processes for bio-based innovations. As countries pursue climate action targets and circular economy models, bioproduction stands out for its ability to reduce reliance on petrochemicals, minimize waste, and produce energy and materials in a more environmentally friendly way. Additionally, the scalability and flexibility of modern bioproduction systems make them suitable for both large-scale industrial applications and localized, on-demand production-providing resilience and adaptability in volatile supply chain environments. The growth of CDMOs and biofoundries is further accelerating market development by offering outsourced, cost-effective access to high-end bioproduction capabilities. Together, these factors are not only fueling rapid expansion but are also setting the stage for bioproduction to become a foundational technology in a bio-based global economy-reshaping the future of how goods and medicines are produced, consumed, and sustained.

SCOPE OF STUDY:

The report analyzes the Bioproduction market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Biologics & Biosimilars, Vaccines, Cell & Gene Therapies, Nucleic Acid Therapeutics); Application (Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application, Cardiovascular Diseases Application); End-Use (BioPharmaceuticals Companies End-Use, Contract Manufacturing Organizations End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AGC Biologics
  • Ajinomoto Bio-Pharma Services
  • BioVectra
  • Boehringer Ingelheim BioXcellence
  • Catalent, Inc.
  • Charles River Laboratories
  • Cytiva
  • Emergent BioSolutions
  • FUJIFILM Diosynth Biotechnologies
  • Genscript Biotech
  • KBI Biopharma
  • Lonza Group
  • MilliporeSigma (Merck KGaA)
  • Novartis
  • Pfizer CentreOne
  • Resilience (National Resilience, Inc.)
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Sartorius AG
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Bioproduction - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Explosive Growth in Biologics and Cell-Based Therapies Throws the Spotlight on Scalable Bioproduction Platforms
    • Personalized Medicine and Rare Disease Treatments Spur Demand for Flexible, Small-Batch Bioproduction Capabilities
    • Here's How Continuous Bioprocessing Is Transforming the Efficiency and Economics of Bioproduction
    • Advancements in Single-Use Systems Drive Cost-Effective and Contamination-Free Production Environments
    • Rise of Contract Development and Manufacturing Organizations Strengthens the Business Case for Outsourced Bioproduction
    • Surging Vaccine and mRNA Therapeutics Pipelines Expand the Addressable Market for Modular Bioproduction Facilities
    • Digitalization and Process Automation Fuel the Emergence of Smart Bioproduction Systems with Real-Time Monitoring
    • Here's the Story: How Cell and Gene Therapy Are Reshaping Facility Design and Custom Bioproduction Workflows
    • Increased Regulatory Focus on Quality by Design Principles Accelerates Adoption of PAT and Data-Driven Bioprocessing
    • Synthetic Biology and Genome Editing Tools Enable High-Yield Production of Novel Bioproducts and Platforms
    • Environmental Sustainability and Energy Efficiency Goals Drive Innovation in Green Bioproduction Methods
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bioproduction Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Bioproduction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics & Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics & Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Biologics & Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cell & Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cell & Gene Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cell & Gene Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Nucleic Acid Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Nucleic Acid Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Nucleic Acid Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for BioPharmaceuticals Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for BioPharmaceuticals Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for BioPharmaceuticals Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Contract Manufacturing Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Contract Manufacturing Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Contract Manufacturing Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Rheumatoid Arthritis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Rheumatoid Arthritis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hematological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hematological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hematological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Diabetes Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Diabetes Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • JAPAN
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • CHINA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: China 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • EUROPE
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Bioproduction by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • FRANCE
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: France 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • GERMANY
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Bioproduction by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • INDIA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: India 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Bioproduction by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Bioproduction by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Bioproduction by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030
  • AFRICA
    • Bioproduction Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Bioproduction by Product - Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Bioproduction by Product - Percentage Breakdown of Value Sales for Biologics & Biosimilars, Vaccines, Cell & Gene Therapies and Nucleic Acid Therapeutics for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Bioproduction by End-Use - BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Bioproduction by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use and Contract Manufacturing Organizations End-Use for the Years 2014, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Bioproduction by Application - Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Bioproduction by Application - Percentage Breakdown of Value Sales for Rheumatoid Arthritis Application, Hematological Disorders Application, Cancer Application, Diabetes Application and Cardiovascular Diseases Application for the Years 2014, 2025 & 2030

IV. COMPETITION